Menu
GWAS Study

Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors.

Ingle JN, Schaid DJ, Goss PE et al.

20876420 PubMed ID
GWAS Study Type
878 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

IJ
Ingle JN
SD
Schaid DJ
GP
Goss PE
LM
Liu M
MT
Mushiroda T
CJ
Chapman JA
KM
Kubo M
JG
Jenkins GD
BA
Batzler A
SL
Shepherd L
PJ
Pater J
WL
Wang L
EM
Ellis MJ
SV
Stearns V
RD
Rohrer DC
GM
Goetz MP
PK
Pritchard KI
FD
Flockhart DA
NY
Nakamura Y
WR
Weinshilboum RM
Chapter II

Abstract

Summary of the research findings

Purpose: We performed a case-control genome-wide association study (GWAS) to identify single nucleotide polymorphisms (SNPs) associated with musculoskeletal adverse events (MS-AEs) in women treated with aromatase inhibitors (AIs) for early breast cancer.

293 cases, 585 controls

Chapter III

Study Statistics

Key metrics and study information

878
Total Participants
GWAS
Study Type
No
Replicated
European
Ancestry
U.S., Canada
Recruitment Country
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.